BioNexus Gene Lab Corp. Payments to Acquire Commercial Real Estate
BioNexus Gene Lab Corp. (BGLC) reported Payments to Acquire Commercial Real Estate of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireCommercialRealEstate · last filed 2025-05-15
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for the quarter ending 2024-12-31 was $6.56K, a 73.35% decline year-over-year.
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for the quarter ending 2024-09-30 was $221.40K, a 21.67% decline year-over-year.
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for the quarter ending 2024-06-30 was $90.52K.
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for fiscal 2024 was $492.73K, a 53.63% increase from fiscal 2023.
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for fiscal 2023 was $320.73K, a 37.32% decline from fiscal 2022.
- BioNexus Gene Lab Corp. payments to acquire commercial real estate for fiscal 2022 was $511.71K.
| Period end | Payments to Acquire Commercial Real Estate 3 month | Payments to Acquire Commercial Real Estate 6 month | Payments to Acquire Commercial Real Estate 9 month | Payments to Acquire Commercial Real Estate 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $6.56K derived: sum of 2 quarters · filed 2025-05-15 | $227.96K derived: sum of 3 quarters · filed 2025-05-15 | $318.49K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $6.56K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $227.96K derived: sum of 2 quarters · filed 2025-04-15 | $318.49K derived: sum of 3 quarters · filed 2025-04-15 | $492.73K 10-K · filed 2025-04-15 |
| 2024-09-30 | $221.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $311.92K derived: sum of 2 quarters · filed 2024-11-15 | $486.17K 10-Q · filed 2024-11-15 | $510.79K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | $90.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $264.77K 10-Q · filed 2024-08-14 | $289.39K derived: sum of 3 quarters · filed 2025-05-15 | $572.06K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | $174.25K 10-Q · filed 2025-05-15 | $198.87K derived: sum of 2 quarters · filed 2025-05-15 | $481.54K derived: sum of 3 quarters · filed 2025-05-15 | $481.33K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $24.62K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $307.29K derived: sum of 2 quarters · filed 2025-04-15 | $307.09K derived: sum of 3 quarters · filed 2025-04-15 | $320.73K 10-K · filed 2025-04-15 |
| 2023-09-30 | $282.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $282.46K derived: sum of 2 quarters · filed 2024-11-15 | $296.11K 10-Q · filed 2024-11-15 | |
| 2023-06-30 | -$202.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $13.44K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $13.65K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $511.71K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |